An observational study in Parkinson Disease, sponsored by Ankara University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Ankara University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 172 studies in Parkinson Disease with a site in Turkey — 50 open to participants now, 56 under way, none of them phase 3. Parkinson Disease · Turkey.
Among the 172 studies in Parkinson Disease with a site in Turkey, this one is the 12th largest by planned enrollment of the 73 observational ones that give a count, is one of 33 that started in 2025, is one of 73 observational ones, reaches primary completion later than 37 of the 55 other live ones, and was the 110th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →50 of the 172 studies in Parkinson Disease with a site in Turkey are open now. Recruiting first, the newest first:
Mustafa Kemal University · Sites in Turkey
Ages 35–75 · Healthy volunteers
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 40+
Acibadem University · Sites in Turkey
Ages 40–85
Kahramanmaras Sutcu Imam University · Sites in Turkey
Ages 40–75
Medipol University · Sites in Turkey
Ages 50–80
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
172 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 33 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 32 across the 99 interventional studies, 61 across the 73 observational. Of the 104 that completed or were terminated, 2 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 172 have an industry lead sponsor. The 10 most frequent:
Ankara University is the lead sponsor of 323 studies on the registry; 65 are open to participants now.
Ankara University has 6 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
18 of the studies in Parkinson Disease with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07678983Izmir Bakircay UniversityWhole-Body Vibration in Parkinson Disease | 2026-12 |
| NCT06154356Karamanoğlu Mehmetbey UniversityAction Observation and Motor Imagery Therapy in Parkinson's Disease | 2026-12 |
| NCT07730073Atlas UniversityEfficacy of LSVT-LOUD Therapy on Voice, Speech, and Quality of Life in Parkinson's Disease | 2026-12 |
| NCT07010783Ankara UniversityRespiratory Functions in Parkinson's Disease | 2026-12-01 |
| NCT07641556Saglik Bilimleri UniversitesiThe Effects of Tele-Rehabilitation-Based Dual-Task Upper Extremity Training in Patients With Parkinson's Disease | 2026-12-01 |
Add all 18 to your calendar (.ics) → With an account.
Among the 172 studies in Parkinson Disease with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim is to examine respiratory functions, inspiratory muscle strength, respiratory function, physical fitness and aerobic capacity in Parkinson's disease patients. Individuals between the ages of 50-80 who have been diagnosed with Parkinson's disease by a neurologist and healthy individuals with similar demographic characteristics will be included in the study as a control group. In addition, patients will be divided into three groups as above and below 2.5 and healthy controls according to the Modified Hoehn and Yahr Scale. Demographic information of the individuals will be recorded and clinical evaluations will be made. The staging of Parkinson's patients will be done with the Modified Hoehn and Yahr Scale, and the severity of the disease will be done with the Unified Parkinson's Disease Rating Scale. The inspiratory muscle strength of the individuals will be evaluated with the PowerBreath K5, respiratory functions with the Pulmonary Function Test device, and physical fitness and aerobic capacity with the Senior Fitness Test.
Patients with Parkinson's disease who came to the neurology outpatient clinic for routine examination and who met the appropriate inclusion criteria and healthy individuals with similar demographic characteristics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
According to the Modified Hoehn and Yahr Scale (MHÖ), patients with a score below 2.5
According to the Modified Hoehn and Yahr Scale (MHÖ), patients with 2.5 and above
Healthy individuals with similar demographic characteristics
Inspiratory Muscle Strength Measurement
In this study, the inspiratory muscle strength of the participants will be measured using the Power Breath device.
Time frame: Baseline
Unified Parkinson's Disease Rating Scale
This scale will evaluate the severity and stage of the participants' Parkinson's disease.
Time frame: Baseline
Evaluation of Respiratory Functions
Participants' respiratory functions will be evaluated using a standard respiratory function test device.
Time frame: Baseline
Senior Fitness Test
The physical fitness levels of the participants will be evaluated using the Senior Fitness Test.
Time frame: Baseline
Plan to share: No
Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 17 months is below that.
Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Apr 2026 → Dec 2026 and completion May 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.